

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 14/815, A61K 38/58</b>		<b>A1</b>	(11) International Publication Number: <b>WO 95/11921</b>
			(43) International Publication Date: 4 May 1995 (04.05.95)
(21) International Application Number: PCT/CA94/00585		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 25 October 1994 (25.10.94)			
(30) Priority Data: 9321951.7 25 October 1993 (25.10.93) GB 9412707.3 24 June 1994 (24.06.94) GB			
(71) Applicant (for all designated States except US): NATIONAL RESEARCH COUNCIL CANADA (NRC-CNRC) [CA/CA]; Montreal Road, Ottawa, Ontario K1A 0R6 (CA).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors; and (75) Inventors/Applicants (for US only): KONISHI, Yasuo [CA/CA]; Apartment 17, 130 Brunswick Boulevard, Kirkland, Quebec H9J 1K8 (CA). SZEWCZUK, Zbigniew [PL/PL]; ul. NA Ostatnim Groszu 40/3, 51-612 Wroclaw (PL). TSUDA, Yuko [JP/JP]; 1440-I, Shimizu, Uozumi-cho, Akashi 674 (JP).			
(74) Agent: MBM & CO.; P.O. Box 809, Station B, Ottawa, Ontario K1P 3P9 (CA).			
(54) Title: BIVALENT THROMBIN INHIBITORS			
(57) Abstract <p>Hirudin is the most potent and specific thrombin inhibitor and is derived from the medicinal leech. It is reported to inhibit thrombin with an equilibrium dissociation constant (<math>K_i</math>) value of <math>2.2 \times 10^{-14}</math> M. synthetic thrombin inhibitors have been designed based on the hirudin sequence but with a dramatically reduced size. The bulky active site inhibitor segment, hirudin<sup>1-48</sup>, has been substituted by small non-substrate type active site inhibitors of thrombin, e.g., dansyl-Arg-(D-pipecolic acid). The linker segment has also been modified using a combination of <math>\omega</math>-amino acids to reduce the molecular weight but retaining sufficient length to span the two principal binding domains. Among the inhibitors designed, dansyl-Arg-(D-pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid) -Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala- (L-<math>\beta</math>-cyclohexylalamine) - (D-Glu) -OH showed the highest affinity and displays a competitive-type inhibition. The incorporation of the non-substrate type active site inhibitor segment and the linker of <math>\omega</math>-amino acids into the bivalent thrombin inhibitors not only improved <i>in vitro</i> thrombin inhibitory activity to the pM level, overcame proteolytic susceptibility at the level of the "normal" scissile bond and conferred high <i>in vivo</i> activity.</p>			

BIVALENT THROMBIN INHIBITORS

5

BACKGROUND OF THE INVENTION

Thrombin plays a central role in the coagulation cascade of higher animals. The primary function of thrombin is to activate fibrinogen to fibrin and generate an insoluble fibrin clot. It also serves regulatory functions in coagulopathy by activating several participating cofactors and proteases such as factor V, factor VIII, factor XIII and protein C. In a pathologic state, thrombin promotes coagulopathy, activates platelets and causes secretion of granular substances that exacerbate the condition. Thrombin's interaction with endothelial cells, smooth muscle cells, fibroblasts, and monocytes/macrophages contribute further to the inflammatory process in thrombotic events. An acute blockage of a coronary artery by a thrombus causes a myocardial infarction. In its early stages, the condition may be alleviated with thrombolytic therapy. However, typical thrombolysis with tissue plasminogen activator, urokinase or streptokinase is problematic. Acute thrombotic reocclusion often occurs after initial successful thrombolysis using these agents. Although the mechanism of reocclusion has not been clearly elucidated, thrombus-bound thrombin may contribute to this problem. Potent and specific agents that neutralize thrombus-bound thrombin would be desirable.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Thrombin is a member of the trypsin family of serine proteases. In addition to the catalytic triad (Asp 102, His 57 and Ser 195) a feature common to the active site of all serine proteases, asp 189 in the primary substrate binding site (S1) of the trypsin family plays an important role in the recognition and binding of substrates and inhibitors.

10 A natural anticoagulant, heparin inhibits thrombin through a mechanism requiring a heparin-antithrombin III compounds. Heparin is known to be poorly accessible to thrombus-bound thrombin. Furthermore, heparin often causes bleeding when used therapeutically and is unable to prevent the occlusive complications in atherosclerotic vascular diseases or reocclusion following successful thrombolysis.

Another agent known to be effective for the inhibition of thrombus-bound thrombin is hirudin. Hirudin is produced by the salivary glands of the European medicinal leech *Hirudo medicinalis* and is a small protein of 65 amino acid residues. It has several potential advantages over other antithrombotics. It is the most potent and specific thrombin inhibitor known having a  $K_i$  value of  $2.2 \times 10^{-14}$  M. Hirudin blocks the active site (AS) and the fibrinogen recognition exosite (FRE) of thrombin simultaneously. Hirudin also inhibits thrombus-bound thrombin as well as circulating thrombin and it has a long half-life of 30-60 minutes when given intravenously or subcutaneously, depending on the

species. Hirudin has very weak antigenicity, and it has no reported acute side effects following intravenous or subcutaneous administration.

5        Synthetic thrombin inhibitors based on the hirudin sequence offer an advantage over native hirudin. They mimic the distinctive mechanism of hirudin and are more readily available through chemical synthesis. The crystal structure of the human  $\alpha$ -thrombin/hirudin complex reveals  
10    that hirudin interacts with the enzyme through an active site inhibitor domain (hirudin<sup>1-48</sup>), a FRE inhibitor segment (hirudin<sup>55-65</sup>), and a linker segment (hirudin<sup>49-54</sup>) which connects these binding components.

15        The bulky active site inhibitor segment, hirudin<sup>1-48</sup>, is sufficiently large and serves to obstruct the enzyme surface. This action has been shown to be simulated when hirudin<sup>1-48</sup> is replaced by a small active site inhibitor segment, D-Phe-Pro-Arg-Pro, with some loss in inhibitory  
20    potency (Maraganore, J.M., Bourdon, P., Jablonsky, J., Ramachandran, K.L., & Fenton, J.W. 11 (1990) *Biochemistry* 29, 7095-7101; DiMaio, J., Gibbs, B., Munn, D., Lefebvre, J. Ni, F., and Konishi, Y., (1990) *J.Biol.Chem* 265, 21698-21703; Bourdon, P., Jablonski, J.-A., Chao, B.H.,  
25    and Maraganore, J.M., 9, (1991) (*FEBS Lett.* 294, 163-166).

Investigators have focused on the use of D-Phe-Pro-Arg-Pro or its analog in the design of active site inhibitors. The crystal structure of D-Phe-Pro-Arg  
30    chloromethylketone (PPACK)-thrombin suggested that the D-Phe-Pro-Arg-Pro in bivalent inhibitors bind to the

thrombin active site in a substrate binding mode, wherein Arg-X is the scissile peptide bond. The active site inhibitor segment, D-Phe-Pro-Arg-Pro, of the bivalent inhibitors is known to be hydrolyzed slowly by thrombin

5 (DiMaio, J., Gibbs, B., Munn, D., Lefebvre, J., Ni, F. and Konishi, Y. (1990) *J. Biol. Chem.* 265, 21698-21703; Witting, J.I., Bourdon, P., Maraganore, J.M., and Fenton, J.W., II (1992) *BioChem. J.* 287, 663-664). The amino acids (D-Phe)-Pro-Arg comprised in the substrate type

10 inhibitor (D-Phe)-Pro-Arg-Pro respectively bind to the S3, S2 and S1 subsites of thrombin.

Hirulog-8<sup>TM</sup> is a bivalent thrombin inhibitor composed of the substrate type inhibitor (D-Phe)-Pro-Arg-Pro, and

15 the native sequence of the hirudin exosite segment 52-65 both linked through a suitable linker (Maraganore et al. US Patent 5,196,404). Since the structure of those thrombin inhibitor is very similar to the structure of hirudin, the interactions of the substrate type active

20 site inhibitor with thrombin are the same as the interactions between the active site of hirudin and thrombin. In addition, it has been shown that the portion (D-Phe)-Pro-Arg-CO can be used in a bivalent thrombin inhibitor (DiMaio et al. International publication WO

25 91/19734). Apparently, the use of the acetyl function at the scissile position gives more resistance to enzyme degradation without affecting the inhibitory activity. The scissile position in a substrate is a position that is recognised by the enzyme and where the hydrolysis

30 takes place. It is therefore advantageous to eliminate or to modify the scissile position in order to give to more

resistance to enzyme degradation. Since the structure of the two classes of bivalent thrombin inhibitors mentioned above are similar to the structure of hirudin, their synthesis is difficult, cumbersome, uses dangerous chemicals and affords low yields of the desired compounds. There is therefore a need for other thrombin inhibitors that would combine high inhibiting activity, enzyme resistance and affordable synthesis.

Besides substrate-type inhibitors, nonsubstrate type inhibitors could be designed to block the active site of thrombin without being cleaved. Examples of these may be derived from arginine and benzamidine to give, for example, (2R,4R)-4-methyl-1-[N<sup>α</sup>-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulphonyl)-L-arginyl]-2-piperidine carboxylic acid (MD-805), N<sup>α</sup>-(4-toluene-sulphonyl)-D,L-amidinophenylalanyl-piperidine (TAPAP), and N<sup>α</sup>-(2-naphthyl-sulphonyl-glycyl)-D-L,p-amidinophenylalanyl-piperidine (NAPAP). These active-site directed synthetic inhibitors have a short half-life of less than several minutes in the circulation. This activity is not of sufficient duration to be effective against the continuous production of thrombin by the patient or against the effect of liberated thrombus bound-thrombin. The characteristic sequence of these compounds starting from the N-terminus is an aromatic group, arginyl or benzamidyl, and piperidide or its analogs. In contrast to hirudin-based sequences, these moieties would be expected to occupy the S3, S1 and S2 subsites of the thrombin active site, respectively.

This mechanism of interaction contrasts with the mode of interaction manifest by substrate-like inhibitors. Accordingly, incorporation of a non-substrate type active site inhibitor into the bivalent inhibitor may have

5 advantages over the substrate like counterparts. For example, a linker attached to the P2 residue piperidide or its analogs could eliminate a labile peptide bond that normally spans the scissile position. The potency of the bivalent inhibitor might be improved because of the

10 higher affinity of the non-substrate type active site-directed segment.

It would be desirable to develop a shortened thrombin inhibitor of the hirudin type. Such a shortened sequence

15 would be easier to synthesize and cheaper to produce. It would have a drastically shortened linear sequence and would be less subject to enzymatic degradation in a mammal.

20 It has been found that such a hirudin-like agent would more likely work well if it blocked both the enzyme activity site of thrombin and the fibrinogen-recognition exosite. It would be even more desirable if both these sequences were chemically connected so as to have both

25 abilities in one compound.

It has been previously reported that the combination of dansyl or dansyl analogues, arginine or benzamidine, and pipercolic acid attaches to the thrombin enzyme activity

30 site. But it has been shown that such activity is weak and not pharmacologically useful (James C. Powers and



Chih-Min Kam, Thrombin: Structure and Function, Chapter  
4, (1992), Lawrence J. Berliner. Plenum Press, New York).

The invention seeks to provide improved bivalent  
5 inhibitors having increased potency and proteolytic  
stability comprising non-substrate type active site  
inhibitor segment.

**Abbreviations.** The following abbreviations have been used in the specification: Abu,  $\gamma$ -aminobutyric acid; Ac, acetyl; Aca,  $\epsilon$ -aminocaproic acid; Aca\*, 8-aminocaprylic acid; Acha, 1-aminocyclohexane-carboxylic acid; Ada, 12-aminododecanoic acid; AMC, 7-amino-4-methylcoumarin; Aua, 11-aminoundecanoic acid; Ava,  $\delta$ -aminovaleric acid; Bal,  $\beta$ -alanine; Boc, *tert*-butoxycarbonyl; BrBzs, 4-bromobenzenesulfonyl; Bzs, benzene sulfonyl; Cha,  $\beta$ -cyclohexylalanine; Fmoc, 9-fluorenylmethoxycarbonyl; FRE, fibrinogen recognition exo site; HPLC, high performance liquid chromatography; MD805, (2R,4R)-4-methyl-1-[N <sup>$\alpha$</sup> -(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulphonyl-glycyl)-L-arginyll]-2-piperidine carboxylic acid; NAPAP, N <sup>$\alpha$</sup> -(2-naphtyl-sulphonyl)-D,L-p-amidinophenylalanyl-piperidide; Nas, naphtylsulfonyl; Nle, norleucine; 3-TAPAP, N <sup>$\alpha$</sup> -(4-toluene-sulphonyl)-D, L-p-amidinophenylalanyl-piperidide; OBzl, benzylester; Pip, pipecolic acid; PPACK, D-Phe-Pro-Arg chloromethylketone; tBbs, 4-*tert*-butylbenzenesulfonyl; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; TipBs, 2,4,6-triisopropylbenzenesulfonyl; TFA, trifluoroacetic acid; Tos, tosyl; Tris, 2-amino-2-(hydroxymethyl)-1,3-propanediol. All amino acid residues are L-configuration unless otherwise indicated. IC<sub>50</sub> is defined as the inhibitor concentration required to double the clotting time relative to the control; means of three determinants  $\pm$  SEM.

Figures and Tables

**Figure 1.** Dixon plot of the hyperbolic and slow competitive inhibition of human  $\alpha$ -thrombin (0.033 NIH unit/mL) by (A) P448 ( $K_i = 17.0 \pm 4.2$  pM) and (B) P498 ( $K_i = 131 \pm 22$  pM), respectively. The fluorogenic assay was performed using Tos-Gly-Pro-Arg-AMC ( $K_s = 3.5$   $\mu$ M and  $V_{max} = 1.4$   $\mu$ M/min) as a substrate at pH 7.8 and 25°C. The amount of product, 7-amino-4-methylcoumarin, is plotted at a substrate concentration of (A) 40  $\mu$ M or (B) 4  $\mu$ M and as a function of various concentrations of inhibitors as a function of time.

**Figure 2.** HPLC profile of the compounds of this invention, more specifically of P448 (A) after 6 hours of incubation with human thrombin, (B) after 3 hours of incubation with human plasma proteases, and (C) after 60 minutes of incubation with kidney membrane homogenates. The peaks at around 3.8 and 33.5 minutes and small peaks at 7.1, 10.6, 27.8, 28.4, 36.5 and 37.0 minutes in (B) are due to the proteins in human plasma. The details of the digestions are described under Experimental Procedures of Example 2.

**Table I** shows  $K_i$  and  $IC_{50}$  values for several thrombin active site directed inhibitors. Their inhibition was analyzed using the method in Segel 1975.

**Table II** shows the  $K_i$  activity values for bivalent inhibitors with various active site inhibitor segments. The exosite segment in all of the examples corresponds to

the amino acid sequence of the exosite on natural hirudin.

5     *Table III* shows the effect of variations within the linker segment Z (the spacer function) on the  $K_i$  and  $IC_{50}$  values of the resulting thrombin inhibitors.

10     *Table IV* shows the effect of the variations within the fibrinogen recognition exosite inhibitor segment,  $G-X_2-G_1-Q-X_3-R_2$ , on the  $K_i$  values of the resulting thrombin inhibitors.

15     *Table V* shows the effect of the variations within the active site segment, the linker segment Z and the fibrinogen recognition exosite inhibitor segment,  $G-X_2-G_1-Q-X_3-R_2$ , on the  $K_i$  values and  $IC_{50}$  of the resulting thrombin inhibitors.

20     *Table VI* shows the effect of the variations within the active site segment, the linker segment Z and the fibrinogen recognition exosite inhibitor segment,  $G-X_2-G_1-Q-X_3-R_2$  in the carotid injury-induced thrombosis assay.

SUMMARY OF THE INVENTION

We have made the surprising discovery that the combination dansyl-arginyl-pipecolic acid and its derivatives have a very strong hirudin-like activity when combined with the natural hirudin exosite oligopeptide sequence - or an analogue thereof - via a suitable linker sequence. The surprising properties of the compounds of this invention reside in the fact that unlike other known bivalent inhibitor, the active site portion of the compound of this invention is a non-substrate-type inhibitor which binds to thrombin in a different S3,S1,S2 pattern. It was therefore surprising that the non-substrate-type active site inhibitor was able to conserve its inhibiting properties in a bivalent form. Furthermore, unlike other known bivalent inhibitor, where the choice of the linker was arbitrary and simply had to be the same as the linker portion of naturally occurring hirudin, the length of the linker of the compounds of the present invention had to be modified because of the different binding pattern of the active site inhibitor. The compounds of the invention are at least 1000 times more active than the dansyl-arginyl-pipecolic acid sequence alone.

25


Surprisingly, the dansylated arginyl pipecolamide compounds acquire dramatically enhanced thrombin specificity when compoundd with an exosite recognizing sequence via a suitable linker. The resulting compounds of this invention demonstrate a substantial advantage compared to the use of an uncomplexed active site

30

compound. Furthermore the compounds of this invention show inhibitory activity comparable to hirudin.


The compounds of this invention are also stable to enzyme degradation. There is therefore a concrete benefit in using the compounds of this invention as thrombin inhibitors.


The compounds of this invention are defined by formula (I) or pharmaceutically acceptable salts thereof:



(I)

wherein, R is selected from the group consisting of:





wherein  $X_4$  is an halogen (e.g., Cl, Br, or F).

- 5 In the compounds of formula (I)  $R_1$  is selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, aryl and aralkyl.  
 $Y$  is selected from the group consisting of alkyl, aryl, and aralkyl.
- 10  $E$  is guanidyl, amidino or hydrogen.  
 $A$  is selected from the group consisting of imino acid residue of either D or L configuration which may be substituted with an alkyl group or an aralkyl group; and hydrophobic amino acid residue.
- 15  $Z$  is a divalent straight-chained saturated or unsaturated linker spanning at least 12 atoms linearly.  
 $P$  is a peptide of at least 6 amino acid or imino acid residues selected from any fibrinogen recognition exosite portion of a hirudin molecule or analogue thereof.

As used in this application, the term « alkyl » represents a saturated or unsaturated; substituted (by a halogen, hydroxyl or C<sub>6-20</sub> aryl) or unsubstituted; straight chain, branched chain, or cyclic hydrocarbon moiety having 1 to 30 carbon atoms and preferably from 1 to 6 carbon atoms this chain or cyclic hydrocarbon moiety may be interrupted by at least one heteroatom such as N, O or S.

The term « aryl » represents a carbocyclic moiety which may be substituted by at least one heteroatom (e.g., N, O or S) and containing one benzenoid-type ring preferably containing from 6 to 15 carbon atoms (e.g., phenyl and naphthyl), this carbocyclic moiety may be interrupted by at least one heteroatom such as N, O or S.

The term « aralkyl » represents an aryl group attached to the adjacent atom by an alkyl group (e.g., benzyl), preferably containing from 6 to 30 carbon atoms.

The term « alkoxyalkyl » represents a substituted or unsubstituted alkyl group containing from 1 to 30 carbon atoms and preferably from 1 to 6 carbon atoms, wherein the alkyl group is covalently bonded to an adjacent element through an oxygen atom (e.g., methoxy and ethoxy).

Unless specified otherwise, the term "amino acid" used herein includes naturally-occurring amino acids as well as non natural analogs as those commonly used by those skilled in the art of chemical synthesis and peptide chemistry. A list of non natural amino acids may be found



in "The Peptides", vol. 5, 1983, Academic Press, Chapter 6 by D.C. Roberts and F. Vellaccio. It is to be noted that unless indicated otherwise, the amino acids used in the context of the present invention are those in the L-configuration.

By a hydrophobic amino acid is usually meant an amino acid that bears an alkyl or aryl group attached to the  $\alpha$ -carbon atom. Thus glycine, which has no such group attached to the  $\alpha$ -carbon atom is not a hydrophobic amino acid. The alkyl or aryl group can be substituted, provided that the substituent or substituents present do not detract from the overall hydrophobic character of the amino acid. Water-solubilizing such as OH, COOH and NH<sub>2</sub> are preferably to be avoided. Examples of hydrophobic amino acids include natural amino acid residues such as alanine; histidine; isoleucine; leucine; phenylalanine; tryptophane; tyrosine; and unnatural amino acid such as those described in "The Peptides", vol. 5, 1983, Academic Press, Chapter 6 by D.C. Roberts and F. Vellaccio. For example, one may cite cyclohexylalanine; 1-aminocyclohexane-carboxylic acid; and subphenylalanine. Subphenylalanine represents the phenylalanine residue bearing substituents on the aromatic ring. Common substituents used by those skilled in the art of amino acid chemistry are halogens (fluoride, bromide, and chloride), electron withdrawing group (NO<sub>2</sub>) or lower alkyl or aryl substituents in the 2, 3, or 4 position.

By acidic amino acid is usually meant an amino acid that bears at least one water-solubilizing substituent

attached to the  $\alpha$ -carbon atom. Said water-solubilizing substituent is independently selected from the group consisting of alkoxy; carboxylic; hydroxyl;  $\text{NH}_2$ ; and carboxyalkyl. Thus glycine, which has no such group

5 attached to the  $\alpha$ -carbon atom, is not an acidic amino acid. Example of acidic amino acids includes natural amino acids residues such as serine; threonine; cysteine; tyrosine; asparagine; glutamine; aspartic acid; glutamic acid; lysine; and unnatural amino acids such as those


10 described in "The Peptides", vol. 5, 1983, Academic Press, Chapter 6 by D.C. Roberts and F. Vellaccio.

By "any fibrinogen recognition exosite portion of a hirudin molecule or analogue thereof" is meant any

15 portion of a hirudin molecule or analogue thereof which binds to the fibrinogen recognition exosite of thrombin.


The term « amino acid residue » refers to a dehydrated amino acid, for example the glycine residue is:

20



The term « imino acid residue » refers to a dehydrated

25 cyclic amino acid, for example the proline is :




Detailed description of the invention

In a preferred embodiment, compounds of this invention are defined by formula (I) wherein,

5

R is selected from the group consisting of:



10 wherein  $X_4$  is an halogen (e.g., Cl, Br, or F).


Y is a linear  $C_{1-6}$  alkyl, phenyl ethyl or phenylmethyl.

E is guanidyl or hydrogen.

A is selected from the group consisting of tetrahydro isoquinoline carboxylate; L or D-pipecolate;


15 aminocyclohexyl carboxylate; and  $\beta$ -cyclohexyl alanine.

In an alternative preferred embodiment, R is selected from the group consisting of



In a preferred embodiment, the chiral center shown as \* in formula (I) is in the L configuration.

- 5 Preferred compounds of this invention are defined by formula (I) wherein P is defined by formula (X):



- 10 wherein,


G and G<sub>1</sub> are independently acidic α-amino acid residues;

X<sub>2</sub> is any hydrophobic α-amino acid residue;

- 15 Q, if present, is a residue derived from an L-α-amino acid or a cyclic imino acid;

X<sub>3</sub>, if present, is any hydrophobic α-amino acid residue;

- 20 R<sub>2</sub> is a hydrophobic oligopeptide having all or a portion of the sequence Pro-Glu-Glu-V-W-X, where V and W are independently hydrophobic amino acid residues and X is selected from the group consisting of D-Glu or L-Glu and Gln; and



- 25 wherein each R<sub>5</sub> is independently selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl;

with the proviso that P consists of at least 6 amino or imino acid residues.

30

Z may preferably comprise an alkyl chain wherein said alkyl chain may be interrupted by one or more atoms of O, S, or N atom, carbonyl or amide group.

Z preferably consist of at least 15 atoms in length comprising at least one  $\omega$ -amino acid.

- 5 Z preferably consist of at least 15 atoms in length comprising at least one  $\alpha$ -amino acid.

In a further embodiment Z preferably consist of at least 15 atoms in length comprising a combination of at least one  $\omega$ -amino acid and at least one  $\alpha$ -amino acid.

In an alternative preferred embodiment, Z is  
 $[\text{NH}-(\text{CHR}_6)_{1-11}-\text{CO}]_{1-4}$ ,  $[\text{NH}-(\text{CH}_2)_{1-11}-\text{CO}]_{1-4}$  or  
 $(\text{NHCH}_2\text{CH}=\text{CHCH}_2\text{CO})_3$   
 15 wherein  $\text{R}_6$  is an alkyl or any naturally occurring amino acid side chain.


Most preferably, Z is selected from the group consisting of: (12-aminododecanoic acid) -4-aminobutyric acid)-; (12-aminododecanoic acid) -6-aminocaproic acid);  
 20 (8-aminocaprylic acid) -4-aminobutyric acid)-; (11-aminoundecanoic acid) -glycyl); (Glycyl)-12-aminododecanoic acid); (12-aminododecanoic acid)-glycyl); and ( $\beta$ -Alanyl-glycyl-glycyl-5-aminovaleric acid).

25



$\text{X}_2$  is preferably Phe or Tyr.

In a preferred embodiment, G and  $\text{G}_1$  may independently be:


30



wherein  $R_3$  is selected from the group consisting of



AND



5

wherein  $R_4$  is hydrogen or alkyl; and  
each  $R_7$  is independently  $CH_3$  or hydrogen.

10 In a further preferred embodiment,  $G$  and  $G_1$  may  
independently be an aspartic acid residue, a glutamic  
acid residue or a glutamic alkyl ester residue.

In a most preferred embodiment,  $G$  and  $G_1$  may  
independently be aspartic or glutamic acid.

15

$Q$  is preferably selected from the group consisting of  
proline residue and glutamic acid residue.

20  $X_3$  is preferably Ile, Leu, allo-Ile or *tert*-butyl  
alanine.

$R_2$  is a hydrophobic oligopeptide having all or a  
portion of the sequence Pro-Glu-Glu-V-W-X, where V-W is

selected from the group consisting of residue of Tyr-Leu, Tyr-Ala, Tyr-( $\beta$ -Cyclohexylalanine), ( $\beta$ -cyclohexylalanine)-Leu, Pro-Tyr, Ala-( $\beta$ -cyclohexylalanine), Phe-Tyr and, ( $\beta$ -cyclohexylalanine)-Ala; and X is selected from the group consisting of D-Glu and Gln.

In a preferred embodiment, V-W would be selected from the group consisting of Tyr-Leu, Tyr-Ala, Tyr-Cha, Cha-Leu, and Cha-Ala.

In a further preferred embodiment, the compounds of this invention may be described by formula (II) said formula (II) comprising an active site portion (AS) and a fibrinogen recognition exosite portion (P) linked through a linker (Z):

## AS-Z-P

(II)

wherein the (AS) portion is preferably selected from the group consisting of Bzs-Arg-(D-Pip); dansyl-Arg-(D-Pip); dansyl-Arg-(L-Pip); dansyl-Nle-(D-Pip); (D-Phe)-Arg-(D-Pip); Fmoc-Arg-(D-Pip); dansyl-Arg-(D-Tic); dansyl-(D-Arg)-(D-Pip); dansyl-Phe-(D-Pip); dansyl-Cha-(D-Pip); (D-Cha)-Arg-(D-Pip);  $\alpha$ -naphthyl sulfonyl-Arg-(D-Pip);  $\beta$ -naphthyl sulfonyl-Arg-(D-Pip); 4-tert-Butyl-benzene sulfonyl-Arg-(D-Pip); dansyl-Arg-(D-Cha); dansyl-Arg-Acha; phenyl ethyl sulfonyl-Arg-(D-Pip);  $\beta$ -dihydroanthracenyl- $\beta$ -sulfonyl-Arg-(D-Pip); (+)-camphorsulfonyl-Arg-(D-Pip); (D-Tic)-Arg-(D-Pip); 4-

bromobenzenesulfonyl-Arg- (D-Pip) and 2,4,6  
triisopropylbenzenesulfonyl-Arg- (D-Pip) .

The (Z) portion is preferably selected from the group  
5 consisting of (12-aminododecanoic acid) -4-aminobutyric  
acid)-; (12-aminododecanoic acid) -6-aminocaproic acid);  
(8-aminocaprylic acid) -4-aminobutyric acid)-;  
(12-aminododecanoic acid) -asparagyl-glycyl); (4-  
aminobutyric acid-glycyl); (5-amino valeric acid)  
10 -glycyl); (6-aminocaproic acid) -glycyl); (7-  
aminoheptanoic acid) -glycyl); (8-aminocaprylic acid)  
-glycyl); (12-aminododecanoic acid); (11-aminoundecanoic  
acid) -glycyl); (Glycyl)-12-aminododecanoic acid);  
(12-aminododecanoic acid)-glycyl); and ( $\beta$ -Alanyl-glycyl-  
15 glycyl-5-aminovaleric acid).

The (P) portion is preferably selected from the group  
consisting of Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-  
Gln-OH; Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L- $\beta$ -  
20 cyclohexylalanine)-(D-Glu)-OH; and Asp-Phe-Glu-Pro-Ile-  
Pro-Tyr-OH.

The biological activity of most of the compounds of  
this invention were evaluated by two different biological  
25 assays. The first assay is an *in vitro* assay that  
evaluates the equilibrium dissociation constant ( $K_i$ ) and  
the inhibitor concentration required to double the time  
to fibrinogen clot formation ( $IC_{50}$ ). The second assay in  
an *in vivo* assay that determines both, the dose of the  
30 compounds of this invention necessary to double the  
occlusion time and the dose of the compounds of this



invention necessary to achieve patency at 60 min. in a carotid injury-induced thrombosis.

As figure (2b) demonstrates, the compounds of this invention, more specifically, P448 was exposed to three types of proteases: 1) thrombin, which forms a complex with the inhibitor and may hydrolyse it, 2) plasma proteases encountered by inhibitors during the blood circulation, and 3) kidney proteases, which are heavily involved in the clearance of the peptides. The compounds of this invention were very stable to enzyme degradation. The compounds of the present invention show an inhibitory activity comparable to the inhibitory activity of hirudin. For example, table II demonstrate that P448, P531, P532 and P540 have  $K_i$  values under 0.032 nM. Table III demonstrates that P527, P501, P500 and P513 have  $K_i$  values under 0.027 nM. Table IV shows that P535 and P551 have  $K_i$  values under 0.00330 nM. Table V shows that BCH-2733 has a  $K_i$  of 0.8 nM.

20

Finally table VI demonstrate the activity of the compounds of this invention in a carotid induced thrombosis model in the rat mediated by  $\text{FeCl}_3$ . For a matter of comparison, two known thrombin inhibitors; Hirulog-8™ and Heparin were also tested. Hirulog-8™ is a thrombin inhibitor having a peptide sequence similar to the peptide sequence of hirudin. The results indicate that the compounds of this invention are capable of inhibiting occlusion in the rat carotid artery at doses in the order of  $\geq 0.25$  mg/kg i.v. The more preferred compounds of this invention confer full arterial patency

30

at dose as low as 0.5-1 mg/kg i.v whereas Hirulog-8™  
which demonstrates patency at 4 mg/kg..

The preferred compounds of this invention are:

- 5 dansyl-Arg-(D-pipecolic acid) - (12-aminododecanoic acid)  
-4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-  
Tyr-Leu-Gln-OH (P448);  
dansyl-Arg-(L-pipecolic acid) - (12-aminododecanoic acid)  
-4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-  
10 Tyr-Leu-Gln-OH (P447);  
dansyl-Nle-(D-Pipecolic acid) - (12-aminododecanoic acid)  
-4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-  
Tyr-Leu-Gln-OH (P493);  
dansyl-Arg-1,2,3,4-tetrahydroisoquinoline-3-carboxylic  
15 acid - (12-aminododecanoic acid) -4-aminobutyric acid)-  
Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P471);  
dansyl-Arg-(D-β-cyclohexylalanine) - (12-aminododecanoic  
acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-  
Glu-Tyr-Leu-Gln-OH (P472);  
20 dansyl-Arg-(D)1-amino cyclohexane carboxylic acid -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P473);  
dansyl-(D-Arg)-(D-Pipecolic acid) - (12-aminododecanoic  
acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-  
25 Glu-Tyr-Leu-Gln-OH (P492);  
dansyl-Phe-(D-Pipecolic acid) - (12-aminododecanoic acid)  
-4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-  
Tyr-Leu-Gln-OH (P476)  
dansyl-Cha-(D-Pipecolic acid) - (12-aminododecanoic acid)  
30 -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-  
Tyr-Leu-Gln-OH (P477);

- $\alpha$ -naphthyl sulfonyl-Arg-(D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P531);
- 5  $\beta$ -naphthyl sulfonyl- Arg-(D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P532);  
benzyl sulfonyl- Arg-(D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P556);
- 10 4-tert-Butyl-benzene sulfonyl-Arg-(D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P552);  
(+) 10-camphorsulfonyl-Arg-(D-Pipecolic acid) -  
(12-aminododecanoic acid) -6-aminocaproic acid- Asp-Phe-  
15 Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P534);  
4-tert-Butyl-benzene sulfonyl- Arg-(D-Pipecolic acid) -  
(12-aminododecanoic acid) -6-aminocaproic acid- Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P540);  
(D- $\beta$ -cyclohexylalanine)-Arg-(D-Pipecolic acid)-  
20 (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P481);  
(D)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-Arg-  
(D-Pipecolic acid)-(12-aminododecanoic acid) -4-  
aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-  
25 Leu-Gln-OH (P482);  
(D-Phe)-Arg-(D-Pipecolic acid)(12-aminododecanoic acid)  
-4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-  
Tyr-Leu-Gln-OH (P483);  
fmoc-Arg-(D-Pipecolic acid)(12-aminododecanoic acid) -4-  
30 aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-  
Leu-Gln-OH (P484);

- dansyl-Arg- (D-Pipecolic acid) - (4-aminobutyric acid)  
-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH  
(P514);
- 5 dansyl-Arg- (D-Pipecolic acid) - (5-amino valeric acid)  
-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH  
(P526);
- dansyl-Arg- (D-Pipecolic acid) - (6-aminocaproic acid)  
-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH  
(P525);
- 10 dansyl-Arg- (D-Pipecolic acid) - (7-aminoheptanoic acid)  
-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH  
(P524);
- dansyl-Arg- (D-Pipecolic acid) - (8-aminocaprylic acid)  
-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH  
15 (P523);
- dansyl-Arg- (D-Pipecolic acid) - (12-aminododecanoic  
acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH  
(P499);
- dansyl-Arg- (D-Pipecolic acid) - (8-aminocaproic acid) -4-  
20 aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-  
Leu-Gln-OH (P528);
- dansyl-Arg- (D-Pipecolic acid) - (11-aminoundecanoic acid)  
-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH  
(P527);
- 25 dansyl-Arg- (D-Pipecolic acid) - (Glycyl)-  
12-aminododecanoic acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-  
Tyr-Leu-Gln-OH (P501);
- dansyl-Arg- (D-Pipecolic acid) - (12-aminododecanoic  
acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-  
30 Gln-OH) (P500);

- dansyl-Arg-(D-Pipecolic acid) - ( $\beta$ -Alanyl-glycyl-glycyl-5-aminovaleric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P498);
- 5 dansyl-Arg-(D-Pipecolic acid) - (6-aminocaproic acid-12-aminododecanoic acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P513);
- dansyl-Arg-(L-Pip) - (4-aminobutyric acid-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P409);
- 10 dansyl-Arg-(L-Pip) - (5-Aminovaleric acid) -glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P547);
- dansyl-Arg-(L-Pip) - (6-aminocaproic acid) -glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P408);
- dansyl-Arg-(L-Pip) - (7-aminoheptanoic acid) -glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P548);
- 15 dansyl-Arg-(L-Pip) - (12-aminododecanoic acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P550);
- dansyl-Arg-(L-pipecolic acid) - (12-aminododecanoic acid)-4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P447);
- 20 dansyl-Arg-(D-pipecolic acid) - (12-aminododecanoic acid)-4-aminobutyric acid)-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L- $\beta$ -cyclohexylalanine)-(D-Glu)-OH (P535);
- $\beta$ -naphthyl sulfonyl-arginyl D-pipecolic acid - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L- $\beta$ -cyclohexylalanine)-(D-Glu)-OH (P551);
- 25 -4-tert-butylbenzenesulfonyl-Arg-(D-pipecolic acid)-(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L- $\beta$ -cyclohexylalanine)-(D-Glu)-OH (P553);
- 30

- $\alpha$ -naphthyl sulfonyl-arginyl D-pipecolic acid -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Tyr-  
Glu-Pro-Ile-Pro-Glu-Glu-Ala- (L- $\beta$ -cyclohexylalanine) - (D-  
Glu) -OH (P581);
- 5 tert-butylbezene-sulfonyl-Arg (D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid) - Asp-Phe-  
Glu-Pro-Ile-Pro-Tyr-OH (BCH-2443);
- tert-butylbezene-sulfonyl-Arg (D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid) - Asp-Phe-  
10 Glu-Pro-Ile-Pro-Tyr -OH (BCH-2736);
- tert-butylbezene-sulfonyl-Arg (D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid) - Asp-Phe-  
Glu-Pro-Ile-Pro-Tyr -OH (BCH-2741);
- 4-bromobenzenesulfonyl-Arg (D-Pipecolic acid) -  
15 (12-aminododecanoic acid) -4-aminobutyric acid) - Asp-Phe-  
Glu-Pro-Ile-Pro-Tyr -OH (BCH-2733); and
- 2,4,6 triisopropylbenzenesulfonyl-Arg (D-Pipecolic acid) -  
(12-aminododecanoic acid) -4-aminobutyric acid) - Asp-Phe-  
Glu-Pro-Ile-Pro-Tyr -OH (BCH-2444).

20

The more preferred compounds of this invention having a  $K_i$  value smaller than 1 nM are;

- (P448); (P471); (P531); (P532); (P552); (P556); (P540);  
(P534); (P528); (P527); (P500); (P501); (P498); (P513);  
25 (P535); (P551); (P581); (P553); and (BCH-2733).

The most preferred compounds of this invention having a  $K_i$  value smaller than 0.1 nM are : (P448); (P531); (P532);

(P540); (P552); (P527); (P500); (P501); (P513); (P535);  
(P551); (P553); and (P581).

It should be noted that a person skilled in the art  
5 could substitute suitable linkers and synthesize variants  
of such active bivalent hirudin-like inhibitors. Several  
such alternative linker segments were synthesized and  
were found to be effective. Table II discloses several  
particularly effective examples. In addition to the  
10 species discussed *supra* some other preferred linkers are  
Ava-glycine, glycine-Ada, Ada-glycine, Bal-glycine-glycine-  
Ava. It should be noted that the bivalent inhibitor  
sequences exemplified in Table III all use the natural  
hirudin exosite.

15

While it may be possible that, for use in therapy, a  
compound of the invention may be administered as the raw  
chemical, it is preferable to present the active  
ingredient as a pharmaceutical formulation.

20

It will be appreciated by those skilled in the art  
that the compounds of formula (I) contain at least one  
chiral centre ( shown as \* in formula I) and thus exist  
in the form of two enantiomers and mixtures thereof. All  
25 such enantiomers and mixtures thereof are included within  
the scope of the invention.

It will be appreciated by those skilled in the art  
that the compounds of formula (I) or (II) may be modified  
30 to provide pharmaceutically acceptable salts thereof  
which are included within the scope of the invention.

Pharmaceutically acceptable salts of the compounds of formula (I) or (II) include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) and (II) and pharmaceutically acceptable acid addition salt thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

In a further embodiment of the present invention is provided the use of a compounds of formula (I) and (II) or a pharmaceutically acceptable salt in the manufacture of a medicament for the treatment of vascular disease in a mammal including human.



In an alternative aspect of the present invention is provided a method for the treatment of vascular disease for the treatment of a mammal, including human comprising  
5 the administration of an effective amount of a compound of formula (I) or (II).

It will be appreciated by people skilled in the art that treatment extends to prophylaxis as well to the  
10 treatment of established vascular disease.

The compounds of the present invention are useful in combinations, formulations and methods for the treatment and prophylaxis of vascular diseases. These diseases  
15 include myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, peripheral arterial occlusion, restenosis following arterial injury or invasive cardiological procedures, acute or chronic atherosclerosis, edema and inflammation, cancer and  
20 metastasis.

The term "combination" as used herein, includes a single dosage form containing at least one compound of this invention and at least one thrombolytic agent, a  
25 multiple dosage form, wherein the thrombin inhibitor and the thrombolytic agent are administered separately, but concurrently, or a multiple dosage form wherein the two components are administered separately, but sequentially.

In sequential administration, the thrombin inhibitor may  
30 be given to the patient during the time period ranging from about 5 hours prior to about 5 hours after

administration of the thrombolytic agent. Preferably, the thrombin inhibitor is administered to the patient during the period ranging from 2 hours prior to 2 hours following administration of the thrombolytic agent.

5

In these combinations, the thrombin inhibitor and the thrombolytic agent work in a complementary fashion to dissolve blood clots, resulting in decreased reperfusion times and increased reocclusion times in patients treated with them. Specifically, the thrombolytic agent dissolves the clot, while the thrombin inhibitor prevents newly exposed, clot-entrapped or clot-bound thrombin from regenerating the clot. The use of the thrombin inhibitor in the formulations of this invention advantageously allows the administration of a thrombolytic reagent in dosages previously considered too low to result in thrombolytic effects if given alone. This avoids some of the undesirable side effects associated with the use of thrombolytic agents, such as bleeding complications.

20

Thrombolytic agents which may be employed in the combinations of the present invention are those known in the art. Such agents include, but are not limited to, tissue plasminogen activator purified from natural sources, recombinant tissue plasminogen activator, streptokinase, urokinase, purokinase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators and known, biologically active derivatives of any of the above.

30

Various dosage forms may be employed to administer the formulations and combinations of this invention. These include, but are not limited to, parenteral administration, oral administration and topical application. The formulations and combinations of this invention may be administered to the patient in any pharmaceutically acceptable dosage form, including those which may be administered to a patient intravenously as bolus or by continued infusion, intramuscularly -- including paravertebrally and periarticularly -- subcutaneously, intracutaneously, intra-articularly, intrasynovially, intrathecally, intra-lesionally, periostally or by oral, nasal, or topical routes. Such compositions and combinations are preferably adapted for topical, nasal, oral and parenteral administration, but, most preferably, are formulated for parenteral administration.

Parenteral compositions are most preferably administered intravenously either in a bolus form or as a constant infusion. For parenteral administration, fluid unit dose forms are prepared which contain the compounds of the present invention and a sterile vehicle. The compounds of this invention may be either suspended or dissolved, depending on the nature of the vehicle and the nature of the particular compounds of this invention. Parenteral compositions are normally prepared by dissolving the compounds of this invention in a vehicle, optionally together with other components, and filter sterilizing before filling into a suitable vial or ampule

and sealing. Preferably, adjuvants such as a local anesthetic, preservatives and buffering agents are also dissolved in the vehicle. The composition may then be frozen and lyophilized to enhance stability.

5

Parenteral suspensions are prepared in substantially the same manner, except that the active component is suspended rather than dissolved in the vehicle. Sterilization of the compositions is preferably achieved by exposure to ethylene oxide before suspension in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of its components.

15

Tablets and capsules for oral administration may contain conventional excipients, such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, and wetting agents. The tablet may be coated according to methods well known in the art. Suitable fillers which may be employed include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include, but are not limited to, starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycolate. Suitable lubricants include, for example, magnesium stearate. Suitable wetting agents include sodium lauryl sulfate.

Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups

30

or elixirs, or may be presented as a dry product for reconstitution with water or another suitable vehicle before use. Such liquid preparations may contain conventional additives. These include suspending agents, 5 such as sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel or hydrogenated edible fats, emulsifying agents which include lecithin, sorbitan monooleate, polyethylene glycols, or acacia, non-aqueous vehicles, 10 such as almond oil, fractionated coconut oil, and oily esters, and preservatives, such as methyl or propyl p-hydroxybenzoate or sorbic acid.

Formulations for topical administration may, for 15 example, be in aqueous jelly, oily suspension or emulsified ointment form.

The dosage and dose rate of the compounds of this invention will depend on a variety of factors, such as the 20 weight of the patient, the specific pharmaceutical composition used, the object of the treatment, i.e., therapy or prophylaxis, the nature of the thrombotic disease to be treated, and the judgment of the treating physician.

25

According to the present invention, a preferred pharmaceutically effective daily dose of the compounds of this invention is between about 1µg/kg body weight of the patient to be treated ("body weight") and about 5 mg/kg 30 body weight. In combinations containing a thrombolytic

agent, a pharmaceutically effective daily dose of the thrombolytic is between about 10% and 80% of the conventional dosage range. The "conventional dosage range" of a thrombolytic agent is the daily dosage used when that agent is employed in a monotherapy [physician's Desk Reference 1989, 43rd Edition, Edward R. Barnhart, publisher]. That conventional dosage range will, of course, vary depending on the thrombolytic agent employed. Examples of conventional dosage ranges are as follows:

urokinase - 500,000 to 6,250,000 units/patient,  
streptokinase - 140,000 to 2,500,000 units/patient, tPA - 0.5 to 5.0 mg/kg body weight, ASPAC - 0.1 to 10 units/kg body weight.

Most preferably, the therapeutic and prophylactic compositions of the present invention comprise a dosage of between about 10  $\mu\text{g/kg}$  body weight and about 500  $\mu\text{g/kg}$  body weight of the compounds of this invention. Most preferred combinations comprise the same amount of the compounds of this invention and between about 10% and about 70% of the conventional dosage range of a thrombolytic agent. It should also be understood that a daily pharmaceutically effective dose of either the compounds of this invention or the thrombolytic agent present in combinations of the invention, may be less than or greater than the specific ranges cited above.

Once improvement in the patient's condition has occurred, a maintenance dose of a combination or composition of this invention is administered, if

necessary. Subsequently, the dosage or the frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to  
5 the desired level, treatment should cease. Patients may, however, require intermittent treatment upon any recurrence of disease symptoms.

According to an alternate embodiment of this  
10 invention, compounds may be used in compositions and methods for coating the surfaces of invasive devices, resulting in a lower risk of clot formation or platelet activation in patients receiving such devices. Surfaces that may be coated with the compositions of this  
15 invention include, for example, prostheses, artificial valves, vascular grafts, stents and catheters. Methods and compositions for coating these devices are known to those of skill in the art. These include chemical cross-linking or physical adsorption of the compounds of this  
20 invention-containing compositions to the surfaces of the devices. According to a further embodiment of the present invention, compounds may be used for ex vivo thrombus imaging in a patient. In this embodiment, the compounds of this invention are labelled with a radioisotope. The  
25 choice of radioisotope is based upon a number of well-known factors, for example, toxicity, biological half-life and detectability. Preferred radioisotopes include, but are not limited to  $^{125}\text{I}$ ,  $^{123}\text{I}$  and  $^{111}\text{I}$ . Techniques for labelling the compounds of this invention are well known  
30 in the art. Most preferably, the radioisotope is  $^{123}\text{I}$  and

the labelling is achieved using  $^{125}\text{I}$ -Bolton-Hunter Reagent. The labelled thrombininhibitor is administered to a patient and allowed to bind to the thrombin contained in a clot. The clot is then observed by  
5 utilizing well-known detecting means, such as a camera capable of detecting radioactivity coupled to a computer imaging system. This technique also yields images of platelet-bound thrombin and meizothrombin.

10 This invention also relates to compositions containing the compounds of this invention and methods for using such compositions in the treatment of tumor metastases. The efficacy of the compounds of this  
15 invention for the treatment of tumor metastases is manifested by the inhibition inhibitors to inhibit thrombin-induced endothelial cell activation. This inhibition includes the repression of platelet activation factor (PAF) synthesis by endothelial cells. These  
20 compositions and methods have important applications in the treatment of diseases characterized by thrombin-induced inflammation and edema, which is thought to be mediated be PAF. Such diseases include, but are not  
25 limited to, adult respiratory distress syndrome, septic shock, septicemia and reperfusion damage. Early stages of septic shock include discrete, acute inflammatory and coagulopathic responses. It has previously been shown that injection of baboons with a lethal dose of live *E. coli* leads to marked declines in neutrophil count, blood pressure and hematocrit. Changes in blood pressure and  
30 hematocrit are due in part to the generation of a disseminated intravascular coagulopathy (DIC) and have



been shown to parallel consumption of fibrinogen [F. B. Taylor et al., "Protein C Prevents the Coagulopathic and Lethal Effects of Escherichia coli infusion in the Baboon", J.Clin.Invest., 79, pp. 918-25 (1987)].

- 5 Neutropenia is due to the severe inflammatory response caused by septic shock which results in marked increases in tumor necrosis factor levels. The compounds of this invention may be utilized in compositions and methods for treating or preventing DIC in septicemia and other  
10 diseases.

This invention also relates to the use of the above-described compounds, or compositions comprising them, as anticoagulants for extracorporeal blood. As used herein,  
15 the term "extracorporeal blood" includes blood removed in line from a patient, subjected to extracorporeal treatment, and then returned to the patient in such processes as dialysis procedures, blood filtration, or blood bypass during surgery. The term also includes  
20 blood products which are stored extracorporeally for eventual administration to a patient and blood collected from a patient to be used for various assays. Such products include whole blood, plasma, or any blood fraction in which inhibition of coagulation is desired.

25

The amount or concentration of compounds of this invention in these types of compositions is based on the volume of blood to be treated or, more preferably, its thrombin content. Preferably, an effective amount of a  
30 compounds of this invention of this invention for

preventing coagulation in extracorporeal blood is from about 1 µg/60 ml of extracorporeal blood to about 5 mg/60 ml of extracorporeal blood.

5       The compounds of this invention may also be used to inhibit clot-bound thrombin, which is believed to contribute to clot accretion. This is particularly important because commonly used anti-thrombin agents, such as heparin and low molecular weight heparin, are  
10       ineffective against clot-bound thrombin. Finally, the compounds of this invention may be employed in compositions and methods for treating neurodegenerative diseases. Thrombin is known to cause neurite retraction, a process suggestive of the rounding in shape changes of  
15       brain cells and implicated in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for  
20       illustrative purposes only and are not to be construed as limiting this invention in any manner.

EXAMPLESExample 1Experimental ProceduresMaterials.

5

Human  $\alpha$ -thrombin (3,000 NIH units/mg), bovine fibrinogen (~70% of protein, 85% of protein clottable), Tos-Gly-Pro-Arg-AMC·HCl salt, poly(ethylene glycol) 8000™, Ada and Tris were purchased from Sigma Inc. AMC dansyl chloride, 1-naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, 4-tert-butylbenzenesulfonyl chloride, Ada, Ava and D,L-Pip were obtained from Aldrich. Boc-Abu, Boc-Bal, Boc-Aca, Boc-Aha, Boc-Cha, Boc-D-Cha, Boc-L-Pip, Boc-D-Pip, and Boc-D-Tic were purchased from BaChem. Acha was obtained from Fluka Inc. Boc-Ada, Boc-D,L-Pip, and Boc-Acha were prepared according to the procedure described by Chaturvedi, D. N., Knittel, J. J., Hruby, V. J., Castrucci, A. M., & Hadley, M. E. (1984) J. Med. Chem. 27, 1406-1410 which is hereby incorporated by reference. All other amino acid derivatives for peptide synthesis were purchased from Advanced ChemTech except Boc-Glu(OBzl)-OH, which was obtained from Sigma. The side chain protecting groups for Boc-amino acids were benzyl for glutamic acid (Glu) and aspartic acid (Asp), tosyl (Tos) for arginine (Arg) and 2-bromobenzyloxycarbonyl for tyrosine (Tyr). Boc-Gln-OCH<sub>2</sub>-phenylacetamidomethyl resin (0.714 mmol/g) and p-methyl-benzhydrylamin resin (0.770 mmol/g) were purchased from Applied Biosystems Inc. Boc-D-Glu(OBzl)-OCH<sub>2</sub>-pheynylacetamidomethyl resin (0.31 mmol/g) was purchased from Peninsula Laboratories, Inc.

The solvents for peptide synthesis were obtained from B&J Chemicals and Applied Biosystems Inc. Citric acid was purchased from Anachemia. HF and TFA were purchased from Matheson and Halocarbon Products Co., respectively.

5

#### Peptide Synthesis

The peptides were prepared according to the method described in Szewczuk, Z., Gibbs, B. F., Yue, S.-Y., Purisima, E., & Konishi, Y. (1992) *Biochemistry* 31, 9132-9140 which is hereby incorporated by reference. Final products were obtained as lyophilizates with 98% or higher purity estimated by analytical HPLC. The purified peptides were identified by amino acid analysis on a Beckman Model 6300™ high performance analyzer and by molecular mass analysis using a SCIEX API III™ mass spectrometer. Peptide contents in lyophilizates were determined by the amino acid analysis.

Following this procedure, the following peptides were synthesized:

20 P429, P428, P431, P430, P396, P448, P447, P471, P472, P473, P476, P477, P493, P492, P531, P532, P556, P552, P540, P534, P482, P482, P483, P484, P514, P526, P525, P524, P523, P499, P528, P527, P501, P500, P498, P513, P409-2, P547, P408-2, P548, P550, P447, P535, P551, P553,

25 P581, BCH-2443, BCH-2736, BCH-2741, BCH-2733, and BCH-2444.

Example 2Proteolytic assays

Proteolytic stabilities of the compounds of this invention against human  $\alpha$ -thrombin and human plasma proteases were measured as described in Szewczuk et al., 1993, *supra*, and Szewczuk et al., 1992, *supra*, respectively. Proteolytic stability of the inhibitors against proteases on kidney membranes was measured as follows: The preparation of kidney membranes was carried out at 0-4°C according to the procedure (method 3) of Maeda, T., Balakrishnan, K., & Mehdi, S. Q. (1983) *Biochim. Biophys. Acta* 731, 115-120. The kidneys of Sprague-Dawley™ rats were minced finely with surgical scissors. The tissue (1 g) was then added to 3 mL of homogenization buffer (10 mM sodium phosphate buffer, pH 7.4, containing 1 mM MgCl<sub>2</sub>, 30 mM NaCl, 0.02% NaN<sub>3</sub> and 10µg/L of DNase) and homogenized using a Polytron\* homogenizer (Brinkmann). For sufficient cell disruption, the tissue was subject to five or six bursts for 5 seconds each time at a power setting of 7 separated by 1 to 2 minutes of cooling. About 10 mL of the homogenate was layered over 10 mL of a 41% (w/v) solution of sucrose and centrifuged in a Beckman SW27™ swinging bucket rotor (100000 x g for 30 minutes). The interfacial membranes were collected and washed twice with 10 mM Tris Hcl buffer, pH 7.4. The suspension of the membranes in the same buffer was stored in small aliquots at -80°C until they were used. The protein content of the suspension were determined before the storage by amino acid analysis. An aliquot of kidney membrane (3 mg) and 3

nM of the inhibitor were then incubated in 0.6 mL of 10 mM sodium phosphate buffer, pH 7.4, containing 1 mM MgCl<sub>2</sub>, 30mM NaCl, 0.02% NaN<sub>3</sub> and 10 µg/L of DNase, for digestion at 37°C. An aliquot (0.15 mL) of the reaction solution was sampled at 0, 15 and 30 minutes of the reaction time. The reaction was terminated by heating at 100°C in a boiling water for 2 minutes. The sample was subsequently spun at 6000 x g for 2 minutes and the supernatant was injected onto a Hewlett Packard Model 1090<sup>TM</sup> HPLC. The inhibitors and their metabolites were isolated on an analytical C18 column (4.6 x 250 mm, Vydac\*) with a linear gradient from 10 to 70% of acetonitrile gradient containing 0.1% trifluoroacetic acid over 60 minutes at a flow rate of 1 mL/min. The elution profile was monitored by the absorbance at 210 nm. The peptides were collected and identified by the amino acid analysis described in Szewczuk et al., 1992, *supra*.

**Materials.** The chromogenic and fluorogenic substrates Tosyl-Gly-Pro-Arg-pNA and Tos-Gly-Pro-Arg-AMC were purchased from Boehringer Mannheim and Sigma, respectively. Fibrinogen and bovine or human  $\alpha$ -thrombins were from Sigma and purity was confirmed by sodium inhibitor dissolved in the same buffer. Initial velocities were recorded at several inhibitor concentrations and kinetic parameters were determined by fitting the data to a general equation describing enzyme inhibition (Segel, 1975). The data were analyzed using the non-linear regression program RNLIN in the IMSL library (IMSL, 1987) on a microVAX<sup>TM</sup> 3500 computer. Dixon

and Lineweaver-Burk plots were constructed to qualitatively assign the type of inhibition exhibited by each peptide. Fluorogenic assays were conducted using the same conditions and instrument as above operating in the fluorescence mode in the ratio ( $\lambda_{\text{ex}} = 383 \text{ nm}$ ,  $\lambda_{\text{em}} = 455 \text{ nm}$ ). Fluorescence intensities were calibrated with 7-amino-4-methyl coumarin solution of known concentration

The results are demonstrated in figures 1 and 2.

10

### Example 3

#### 15 Fibrin Clotting and Amidolytic Assays

**Materials.** The chromogenic and fluorogenic substrates Tosl-Gly-Pro-Arg-pNA and Tos-Gly-Pro-Arg-AMC were purchased from Boehringer Mannheim and Sigma, respectively. Fibrinogen and bovine or human  $\alpha$ -thrombins were from Sigma and purity was confirmed by sodium inhibitor dissolved in the same buffer.

The fibrin clotting assay was performed in 50 mM Tris HCl buffer (pH 7.52 at 37 °C) containing 0.1 M NaCl and 0.1% poly(ethylene glycol) 8000 with  $9.0 \times 10^{-10} \text{ M}$  (0.1 NIH unit/mL) and 0.03 % (w/v) of the final concentrations of human thrombin and bovine fibrinogen, respectively, as reported elsewhere (Szewczuk et al., 1992). The clotting time was plotted against the inhibitor concentrations and the IC<sub>50</sub> was estimated as the inhibitor concentration

30

required to double the clotting time relative to the control.

DETERMINATION OF THROMBIN INHIBITORY DISSOCIATION CONSTANTS  $K_i$

5

The inhibition of the amidolytic activity of human thrombin was measured fluorometrically using Tos-Gly-Pro-Arg-AMC as a fluorogenic substrate in 50 mM Tris-HCl buffer (pH 7.52 at 37 °C) containing 0.1 M NaCl and 0.1% poly(ethylene glycol) 8000 at room temperature (Szewczuk et al., 1992). The final concentrations of the inhibitors, the substrate and human thrombin were 0.1-5-fold of  $K_i$ ,  $1-8 \times 10^{-5}$  M and  $6.0 \times 10^{-11}$  M, respectively for the data in Table 1. For data in Tables II and III, the corresponding concentrations were 0.5-<sup>TM</sup>1000-fold of  $K_i$ ,  $1-8 \times 10^{-6}$  M and  $3.0 \times 10^{-11}$  M, respectively, if  $K_i > 10^{-10}$  M, and 10-100-fold of  $K_i$ ,  $5-40 \times 10^{-6}$  M and  $3.0 \times 10^{-11}$  M, respectively, if  $K_i < 10^{-10}$  M. The hydrolysis of the substrate by thrombin was monitored on a Varian-Cary 2000<sup>TM</sup> spectrophotometer in the fluorescence mode ( $\lambda_{ex} = 383$  nm,  $\lambda_{em} = 455$  nm) or on a Hitachi F2000<sup>TM</sup> fluorescence spectrophotometer ( $\lambda_{ex} = 383$  nm,  $\lambda_{em} = 455$  nm), and the fluorescent intensity was calibrated using AMC. The reaction reached a steady-state within 3 min after mixing thrombin with the substrate and an inhibitor. The steady-state velocity was then measured for a few minutes. The compounds of this invention were also pre-incubated with thrombin for 20 min at room temperature before adding the substrate. The steady-state was achieved within 3 min and measured for a few min. The kinetic data (the steady-state

10  
15  
20  
25  
30



velocity at various concentrations of the substrate and the inhibitors) of the competitive inhibition was analyzed using the methods described by Segel (1975). A non-linear regression program, RNLIN in the IMSL library (IMSL, 1987),  
5 LMDER in MINPACK library (More et al., 1980) or Microsoft™ Excell™, was used to estimate the kinetic parameters ( $K_m$ ,  $V_{max}$  and  $K_i$ ).

The biological data are reported on tables I-V.

**Table I**  
**Activities of the Thrombin Active Site Directed inhibitors**

Peptide	Sequence	K <sub>i</sub> (nM)	IC <sub>50</sub> (nM)
P429	Dansyl-Arg-(D-Pipecolic acid)-NH <sub>2</sub>	158±57	430±130
P428	Dansyl-Arg-(L-Pip)-NH <sub>2</sub>	19100±1300	37900±1900
P431	Dansyl-Arg-(D-Pipecolic acid)-Abu-NH <sub>2</sub>	980±130	2580±680
p430	Dansyl-Arg-(L-Pip)-Abu-NH <sub>2</sub>	11600±3300	39100±7200
P396	Dansyl-Arg-(D-Tic)-NH <sub>2</sub>	390±20	820±150

**Table II**  
**Activity of Thrombin Inhibitors with Various Active Site**  
**Inhibitor Segments**

PEPTIDE	Structure of active site inhibitor segment	K <sub>i</sub> (nM)
P448	Dansyl-Arg-(D-Pipecolic acid) <sup>a</sup>	0.0170±0.0042
P447	Dansyl-Arg-(L-Pip) <sup>a</sup>	12.4±1.8
P471	Dansyl-Arg-(D-Tic) <sup>a</sup>	0.285±0.040
P472	Dansyl-Arg-(D-Cha) <sup>a</sup>	17.1±3.1
P473	Dansyl-Arg-D-(Acha) <sup>a</sup>	36.3±10.3
P476	Dansyl-Phe-(D-Pipecolic acid) <sup>a</sup>	2.62±0.20
P477	Dansyl-cha-(D-Pipecolic acid) <sup>a</sup>	5.85±0.098
P493	Dansyl-Nle-(D-Pipecolic acid) <sup>a</sup>	5.20±1.31
P492	Dansyl-(D-Arg)-(D-Pipecolic acid) <sup>a</sup>	1.02±0.38
P531	α-Nas-Arg-(D-Pipecolic acid) <sup>a</sup>	0.032±0.001
P532	β-Nas-Arg-(D-Pipecolic acid) <sup>a</sup>	0.024±0.004
P556	Bzs-Arg-(D-Pipecolic acid) <sup>a</sup>	0.137±0.026
P552	tBbs-Arg-(D-Pipecolic acid) <sup>a</sup>	0.0170±0.0004
P540	tBbs-Arg-(D-Pipecolic acid) <sup>b</sup>	0.0053±0.0006
P534	(+) 10-camphorsulfonyl-Arg-(D-Pipecolic acid) <sup>b</sup>	0.108±0.001
P481	(D-Cha)-Arg-(D-Pipecolic acid) <sup>a</sup>	9.51±0.16
P482	(D-Tic)-Arg-(D-Pipecolic acid) <sup>a</sup>	12.2±3.2
P483	(D-Phe)-Arg-(D-Pipecolic acid) <sup>a</sup>	54.9±6.6
P484	fmoc-Arg-(D-Pipecolic acid) <sup>a</sup>	14.8±1.2
	Hirudin	0.00028

a. The linker and exosite inhibitor segments comprise the sequence Ada-Abu-DFEEIPEEYLQ-OH.

b The linker and exosite inhibitor segments comprise the sequence Ada-Aca- DFEEIPEEYLQ-OH.

TABLE III  
Activity of Thrombin Inhibitors with Various Linker Serments

Peptide	Structure of Linker Segment	Atom No. Lenght	Ki (nM)
P514	Abu-Gly <sup>a</sup>	8	6800 ± 1640
p526	Ava-Gly <sup>a</sup>	9	4970 ± 260
P525	Aca-Gly <sup>a</sup>	10	3000 ± 830
P524	Aha-Gly <sup>a</sup>	11	1480 ± 170
P523	Aca*-Gly <sup>a</sup>	12	148 ± 9
P499	Ada <sup>a</sup>	13	20.0 ± 4.0
P528	Aca*-Abu <sup>a</sup>	14	0.521 ± 0.086
P527	Aua-Gly <sup>a</sup>	15	0.0260 ± 0.0044
P501	Gly-Ada <sup>a</sup>	16	0.0271 ± 0.0067
P500	Ada-Gly <sup>a</sup>	16	0.0255 ± 0.0100
P498	βAla-Gly-Gly-Ava <sup>a</sup>	16	0.131 ± 0.022
P448	Ada-Abu <sup>a</sup>	18	0.0170 ± 0.0042
P513	Ada-Aca <sup>a</sup>	20	0.0155 ± 0.0026
P409-2	Abu-Gly <sup>b</sup>	8	no inhibition
P547	Ava-Gly <sup>b</sup>	9	--
P408-2	Aca-Gly <sup>b</sup>	10	124 ± 61
P548	Aha-Gly <sup>b</sup>	11	--
P550	Ada <sup>b</sup>	13	--
P447	Ada-Abu <sup>b</sup>	18	12.4 ± 1.8
	Hirudin		0.00028

- a. The active site inhibitor and exosite inhibitor segments comprise the sequences dansyl-Arg-(D-Pipecolic acid) and DFEEIPEEYLO-OH, respectively.
- b. The active site inhibitor and exosite inhibitor segments comprise the sequences dansyl-Arg-(L-Pip) and DFEEIPEEYLO-OH, respectively.

**TABLE IV**  
**Activity of Thrombin Inhibitors with Various Exosite Inhibitor Serments**

Peptide	Structure of active,site inhibitor segment	Structure of,exosite inhibitor segment	K <sub>i</sub> (nM)
P535	Dansyl-Arg-(D-Pipecolic acid) <sup>a</sup>	DYEPIPEEA-(Cha)-(D-Glu)-OH	0.00123 ± 0.00026 <sup>1</sup> 0.0020±0.0004 <sup>2</sup>
P551	β-Nas-Arg-(D-Pipecolic acid) <sup>a</sup>	DYEPIPEEA-(Cha)-(D-Glu)-OH	0.00330 ± 0.00016 <sup>1</sup> 0.0042±0.0002 <sup>2</sup>
P553	tBbs-Arg-(D-Pipecolic acid) <sup>a</sup>	DYEPIPEEA-(Cha)-(D-Glu)-OH	0.0030±0.0004
P581	α-Nas-Arg-(D-Pipecolic acid) <sup>a</sup>	DYEPIPEEA-(Cha)-(D-Glu)-OH	0.0145±0.0009

a: the linker segment comprise the sequences (12-aminododecanoic acid) - (4-aminobutyric acid)

1 results from assay no. 1

2 results from assay no. 2

**TABLE V**  
**Activity of Thrombin Inhibitor**

Peptide	Active site	Linker	Exosite	Ki	IC <sub>50</sub> (dt)
BCH-2443	tBbs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	1nM	12.0nM
BCH-2736	tBbs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	270nM	1.1μM
BCH-2741	tBbs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	not tested due to insolubility	
BCH-2733	BrBs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	0.8nM	4.1nM
BCH-2444	tipBs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	5.5nM	55.0nM

Example 4FeCl<sub>3</sub> Induced Arterial Injury Model

Specie: Rat, male, Sprague-Dawley.

Weight: 375-450g

Experimental Study

The FeCl<sub>3</sub> induced arterial injury model assays were conducted according to Kurz, K.D., Main, R.W., Sandusky, G.E., Thrombosis research 60; 269-280, 1990 and Schumacher, W.A. et al. J. pharmacology and experimental therapeutics 267; 1237-1242, 1993.

Male, Sprague-Dawley ( 375- 450 g) are anesthetized with Urethane ( 1500 mg/kg IP). Animals are laid on a heating pad which is maintained at 37°C. The carotid artery is approached through a midline cervical incision. Carefully blunt dissection is used to expose and isolate the vessel from the carotid sheath. Using forceps, the artery is lifted to provide clearance to insert two small polyethylene tubing (PE-205) underneath it. The temperature probe (Physitemp MT23/3)<sup>TM</sup> is placed between the PE-205 and the artery. The vessel temperature is monitored for 60 minutes after application of FeCl<sub>3</sub>. Vessel temperature changes are recorded on a thermister (Cole-Palmer Model 08533-41). Injury is induced by application of a small disc (3 mm dia.) of Whatman<sup>TM</sup> No.1 filter paper previously dipped in a 35% solution of FeCl<sub>3</sub> on the carotid artery above the temperature probe. The

site of the experiment is covered with in Aluminum foil in order to protect the  $\text{FeCl}_3$  from degradation by light.

The time between the Ferric Chloride application and the time at which the vessel temperature decreases abruptly ( $>2.4^\circ\text{C}$ ), is recorded as the time to occlusion (TTO) of the vessel.

Before the start of the experiment, one blood sample is drawn (1 ml) in a tube of 0.105M buffered citrate solution (from the eye's sinus) and the animal is exsanguinated at the end. All the samples are kept on ice and centrifuged as soon as possible at 2000 Rpm for 10 min.,  $4^\circ\text{C}$ . The plasma is analyzed in duplicate for activated partial thromboplastin time on a haemostasis analyzer (STAGO ST4<sup>TM</sup>).

From a group of four animals, two arteries are stored at  $-80^\circ\text{C}$  for further analysis. The others are observed under a light microscope at 40X (Leica<sup>TM</sup>) for quantification of the occlusion ( complete, partial, no occlusion).

The biological data are reported on table VI.



**TABLE VI**  
**Activity of Thrombin Inhibitor in a Carotid injury-induced thrombosis**


Peptide	Active site	Linker	Exosite	Dose to double occlusion time (mg/kg <i>i.v.</i> bolus) <sup>1</sup>	Dose to achieve patency at 60min. (mg/kg <i>i.v.</i> bolus) <sup>2</sup>
P448	Dansyl-Arg-(D-Pipecolic acid)	Ada-Abu	DFEEIPEEYL Q-OH	1.0 (N = 3)	not achieved at 2 (N = 3)
P531	$\alpha$ Nas-Arg (D-Pipecolic acid)	Ada-Abu	DFEEIPEEYL Q-OH	0.5 (N = 4)	not achieved at 2 (N = 4)
P540	tBbs-Arg-(D-Pipecolic acid)	Ada-Aca	DFEEIPEEYL Q-OH	0.5 (N = 4)	not achieved at 2 (N = 4)
P551	$\beta$ Nas-Arg (D-Pipecolic acid)	Ada-Abu	DYEPIPEEA-(Cha)-(D-Glu)-OH	0.5-1 (N = 5)	1-2 (N = 5)
P552	tBbs-Arg-(D-Pipecolic acid)	Ada-Abu	DFEEIPEEYL Q-OH	0.5 (N = 4)	$\geq 2$ (N = 4)
P553	tBbs-Arg-(D-Pipecolic acid)	Ada-Abu	DYEPIPEEA-(Cha)-(D-Glu)-OH	0.25 (N = 4)	0.5-1 (N = 4)
P532	$\beta$ Nas-Arg (D-Pipecolic acid)	Ada-Abu	DFEEIPEEYLQ-OH	0.5-1 (N = 4)	1-2 (N = 4)
P581	$\alpha$ Nas-Arg (D-Pipecolic acid)	Ada-Abu	DYEPIPEEA-(Cha)-(D-Glu)-OH	0.5 (N = 3)	1 (N = 3)
BCH-2443	tBbs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	not achieved at 4 (N = 1)	not achieved at 4 (N = 1)
BCH-2736	tBbs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	4 (N = 2)	not achieved at 4 (N = 2)
BCH-2741	tBbs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	not tested due to insolubility	
BCH-2733	BrBs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	not achieved at 2 (N = 4)	not achieved at 2 (N = 4)
BCH-2444	tipBs-Arg (D-Pipecolic acid)	Ada-Abu	DFEPIPY-OH	not tested due to insolubility	
Hirulog™				2 (N = 4)	4 (N = 4)
Heparin				200U/Kg (N = 4)	not achieved at 400 U/Kg (N = 4)

<sup>1</sup> control occlusion time is  $19 \pm 1$  min (N = 11)  
<sup>2</sup> as defined by no drop in vessel temperature

What is claimed is:

5


1. A compound of formula (I) or pharmaceutically acceptable salts thereof:




Wherein,

(I)

- 10 R is selected from the group consisting of :





wherein,

$X_4$  is an halogen (e.g., Cl, Br, or F);

5  $R_1$  is selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, aryl and aralkyl;

$Y$  is selected from the group consisting of alkyl, aryl, and aralkyl;


$E$  is guanidyl, amidino or hydrogen;

10  $A$  is selected from the group consisting of imino acid residue of either D or L configuration which may be substituted with an alkyl group or an aralkyl group; and hydrophobic amino acid residue;

15  $Z$  is a divalent straight-chained saturated or unsaturated linker spanning at least 12 atoms linearly; and

20  $P$  is peptide of at least 6 amino or imino acid residues selected from any fibrinogen recognition exosite portion of a hirudin molecule or an analogue thereof.

2. A compound according to claim 1 wherein,  
R is selected from the group consisting of:




wherein  $X_4$  is an halogen (e.g., Cl, Br, or F);  
Y is a linear  $C_{1-6}$  alkyl, phenyl ethyl or  
phenylmethyl;

E is guanidyl or hydrogen; and


A is selected from the group consisting of  
tetrahydro isoquinoline carboxylate; L or D-pipecolate;  
aminocyclohexyl carboxylate; and  $\beta$ -cyclohexyl alanine.

3. A compound according to claim 1 wherein,  
R is selected from the group consisting of



4. A compound according to anyone of claims 1 to 3  
wherein the chiral center \* in formula(I) is in the L  
configuration.

5. A compound according to claim 1 wherein P is defined  
5 by formula (X):



10

wherein:

G and G<sub>1</sub> are independently acidic α-amino acid residues;


X<sub>2</sub> is any hydrophobic α-amino acid residue;

15 Q, if present, is a residue derived from an L-α-amino acid or a cyclic imino acid;

X<sub>3</sub>, if present, is any hydrophobic α-amino acid residue;

20 R<sub>2</sub> is a hydrophobic oligopeptide having all or a portion of the sequence Pro-Glu-Glu-V-W-X, where V and W are independently hydrophobic amino acid residues and X is selected from the group consisting of D-Glu or L-Glu and Gln; and

25



wherein each R<sub>5</sub> is independently selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl;

30


with the proviso that P consists of at least 6 amino or imino acid residues.

6. A compound according to claim 1 wherein Z is an alkyl chain that may be interrupted by one or more heteroatom  
35 selected from: O, S, and N; a carbonyl group; or an amide group.

7. A compound according to claim 1 wherein Z consist of at least 15 atoms in lenght comprising at least one  $\omega$ -amino acid.
- 5 8. A compound according to claim 1 wherein Z consist of at least 15 atoms in lenght comprising at least one  $\alpha$ -amino acid.
- 10 9. A compound according to claim 1 wherein Z consist of at least 15 atoms in lenght comprising a combination of at least one  $\omega$ -amino acid and at least one  $\alpha$ -amino acid.
- 15 10. A compound according to claim 1 wherein Z is  $[\text{NH}-(\text{CHR}_6)_{1-11}-\text{CO}]_{1-4}$ ,  $[\text{NH}-(\text{CH}_2)_{1-11}-\text{CO}]_{1-4}$ , or  $(\text{NHCH}_2\text{CH}=\text{CHCH}_2\text{CO})_3$ , wherein  $\text{R}_6$  is an alkyl or any naturally occuring amino acid residue.
- 20 11. A compound according to claim 1 wherein Z is selected from the group consisting of: (12-aminododecanoic acid) -4-aminobutyric acid)-; (12-aminododecanoic acid) -6-aminocaproic acid); (8-aminocapylic acid) -4-aminobutyric acid)-; (11-aminoundecanoic acid) -glycyl); (Glycyl)-12-aminododecanoic acid); (12-aminododecanoic acid)-glycyl); and ( $\beta$ -Alanyl-glycyl-glycyl-5-aminovaleric acid.
- 25 12. A compound according to claim 4 wherein:  
G and  $\text{G}_1$  are independently acidic  $\alpha$ -amino acid residues;  
30  $\text{X}_2$  is Phe or Tyr;  
Q is selected from the group consisting of proline residue and glutamic acid residue;  
 $\text{X}_3$  is Ile, Leu, allo-Ile or tert-butyl alanine;  
35 and  
 $\text{R}_2$  is an hydrophobic oligopeptide having all or a portion of the sequence Pro-Glu-Glu-V-W-X, where V-W is



selected from the group consisting of residue of Tyr-Leu, Tyr-Ala, Tyr-( $\beta$ -Cyclohexylalanine), ( $\beta$ -cyclohexylalanine)-Leu, Pro-Tyr, Ala-( $\beta$ -cyclohexylalanine), Phe-Tyr and, ( $\beta$ -cyclohexylalanine)-Ala; and X is selected from the group consisting of D-Glu and Gln.

13. A compound according to claim 12 wherein G and G<sub>1</sub> are independently:




10

wherein R<sub>3</sub> is selected from the group consisting of



AND



15 wherein R<sub>4</sub> is hydrogen or alkyl; and each R<sub>7</sub> is independently CH<sub>3</sub> or hydrogen.

14. A compound according to claim 12 wherein G and G<sub>1</sub> are independently an aspartic acid residue, a glutamic acid residue or a glutamic alkyl ester residue.

15. A compound according to claim 12 wherein G and G<sub>1</sub> may independently be residues of aspartic or glutamic acid.

25

16. A compound according to claim 12 wherein V-W is selected from the group consisting of Tyr-Leu; Tyr-Ala; Tyr-( $\beta$ -cyclohexylalanine); ( $\beta$ -cyclohexylalanine)-Leu;

and ( $\beta$ -cyclohexylalanine)-Ala.

17. A compound of formula (II):

5

**AS-Z-P**

(II)

wherein,

AS is an active site portion,

10

Z is a linker portion,

P is a fibrinogen recognition exosite portion,

wherein:

the active site portion (AS) is selected from the group consisting of benzyl sulfonyl-Arg-(D-pipecolic); dansyl-Arg-(D-pipecolic); dansyl-Arg-(L-pipecolic); dansyl-Nle-(D-pipecolic); (D-Phe)-Arg-(D-pipecolic); 9-fluorenylmethoxycarbonyl-Arg-(D-pipecolic); dansyl-Arg-(D)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; dansyl-(D-Arg)-(D-pipecolic); dansyl-Phe-(D-pipecolic); dansyl-( $\beta$ -cyclohexylalanine)-(D-pipecolic); (D- $\beta$ -cyclohexylalanine)-Arg-(D-pipecolic);  $\alpha$ -naphthyl sulfonyl-Arg-(D-pipecolic);  $\beta$ -naphthyl sulfonyl-Arg-(D-pipecolic); 4-tert-Butyl-benzene sulfonyl-Arg-(D-Pipecolic); dansyl-Arg-(D-cyclohexylalanine); dansyl-Arg-Acha; phenyl ethyl sulfonyl-Arg-(D-pipecolic);  $\beta$ -dihydroanthracenyl- $\beta$ -sulfonyl-Arg-(D-pipecolic); (+)-camphorsulfonyl-Arg-(D-pipecolic); 4-bromobenzenesulfonyl-Arg-(D-pipecolic); (D)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate-Arg-(D-pipecolic); and 2,4,6-triisopropylbenzenesulfonyl-Arg-(D-pipecolic);

the linker portion (Z) is selected from the group consisting of (12-aminododecanoic acid) -4-aminobutyric acid)-; (12-aminododecanoic acid) -6-aminocaproic acid); (8-aminocaprylic acid) -4-aminobutyric acid)-; (12-aminododecanoic acid) -asparagyl-glycyl); (4-



aminobutyric acid-glycyl); (5-amino valeric acid)  
-glycyl); (6-aminocaproic acid) -glycyl); (7-  
aminoheptanoic acid) -glycyl); (8-aminocaprylic acid)  
-glycyl); (12-aminododecanoic acid); (11-  
5 aminoundecanoic acid) -glycyl); (Glycyl)-  
12-aminododecanoic acid); (12-aminododecanoic acid)-  
glycyl); and ( $\beta$ -Alanyl-glycyl-glycyl-5-aminovaleric  
acid); and

10 the fibrinogen recognition exosite portion (P) is  
selected from the group consisting of Asp-Phe-Glu-Glu-  
Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH; Asp-Tyr-Glu-Pro-Ile-  
Pro-Glu-Glu-Ala- (L- $\beta$ -cyclohexylalanine) - (D-Glu) -OH; and  
Asp-Phe-Glu-Pro-Ile-Pro-Tyr-OH.

15 18. A compound according to claim 17 wherein said  
compound is selected from the group consisting of:  
dansyl-Arg-(D-pipecolic acid) - (12-aminododecanoic  
20 acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-  
Glu-Glu-Tyr-Leu-Gln-OH (P448);  
dansyl-Arg-(L-pipecolic acid) - (12-aminododecanoic  
acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-  
Glu-Glu-Tyr-Leu-Gln-OH (P447);  
25 dansyl-Nle-(D-Pipecolic acid) - (12-aminododecanoic  
acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-  
Glu-Glu-Tyr-Leu-Gln-OH (P493);  
dansyl-Arg-1,2,3,4-tetrahydroisoquinoline-3-carboxylic  
acid - (12-aminododecanoic acid) -4-aminobutyric acid)-  
30 Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P471);  
dansyl-Arg-(D- $\beta$ -cyclohexylalanine) -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-  
Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P472);  
dansyl-Arg-(D)1-amino cyclohexane carboxylic acid -  
35 (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-  
Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P473);  
dansyl-(D-Arg)-(D-Pipecolic acid) - (12-aminododecanoic

- acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P492);
- dansyl-Phe-(D-Pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P476)
- 5 dansyl-( $\beta$ -cyclohexylalanine)-(D-Pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P477);
- $\alpha$ -naphthyl sulfonyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P531);
- 10  $\beta$ -naphthyl sulfonyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P532);
- 15 benzyl sulfonyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P556);
- 4-tert-Butyl-benzene sulfonyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P552);
- 20 (+) 10-camphorsulfonyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid) -6-aminocaproic acid- Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P534);
- 4-tert-Butyl-benzene sulfonyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid) -6-aminocaproic acid- Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P540);
- 25 (D- $\beta$ -cyclohexylalanine)-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P481);
- 30 (D)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-Arg-(D-Pipecolic acid)-(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P482);
- (D-Phe)-Arg-(D-Pipecolic acid)(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P483);
- 35 fmoc-Arg-(D-Pipecolic acid)(12-aminododecanoic acid)


- 4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P484);  
dansyl-Arg-(D-Pipecolic acid) - (4-aminobutyric acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P514);  
5 dansyl-Arg-(D-Pipecolic acid) - (5-amino valeric acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P526);  
dansyl-Arg-(D-Pipecolic acid) - (6-aminocaproic acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P525);  
10 dansyl-Arg-(D-Pipecolic acid) - (7-aminoheptanoic acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P524);  
dansyl-Arg-(D-Pipecolic acid) - (8-aminocaprylic acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P523);  
15 dansyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P499);  
20 dansyl-Arg-(D-Pipecolic acid) - (8-aminocaproic acid)-4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P528);  
dansyl-Arg-(D-Pipecolic acid) - (11-aminoundecanoic acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P527);  
25 dansyl-Arg-(D-Pipecolic acid) - (Glycyl)-12-aminododecanoic acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P501);  
30 dansyl-Arg-(D-Pipecolic acid) - (12-aminododecanoic acid)-glycyl)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P500);  
dansyl-Arg-(D-Pipecolic acid) - ( $\beta$ -Alanyl-glycyl-glycyl-5-aminovaleric acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P498);  
35 dansyl-Arg-(D-Pipecolic acid) - (6-aminocaproic acid-12-aminododecanoic acid)-Asp-Phe-Glu-Glu-Ile-Pro-Glu-

- Glu-Tyr-Leu-Gln-OH (P513);  
dansyl-Arg-(L-Pip) - (4-aminobutyric acid-glycyl)-Asp-  
Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P409);  
dansyl-Arg-(L-Pip) - (5-Aminovaleric acid) -glycyl)-  
5 Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P547);  
dansyl-Arg-(L-Pip) - (6-aminocaproic acid) -glycyl)-  
Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P408);  
dansyl-Arg-(L-Pip) - (7-aminoheptanoic acid) -glycyl)-  
Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P548);  
10 dansyl-Arg-(L-Pip) - (12-aminododecanoic acid)-Asp-Phe-  
Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH (P550);  
dansyl-Arg-(L-pipecolic acid) - (12-aminododecanoic  
acid) -4-aminobutyric acid)-Asp-Phe-Glu-Glu-Ile-Pro-  
Glu-Glu-Tyr-Leu-Gln-OH (P447);  
15 dansyl-Arg-(D-pipecolic acid) - (12-aminododecanoic  
acid) -4-aminobutyric acid)-Asp-Tyr-Glu-Pro-Ile-Pro-  
Glu-Glu-Ala-(L- $\beta$ -cyclohexylalanine)-(D-Glu)-OH (P535);  
 $\beta$ -naphthyl sulfonyl-arginyl D-pipecolic acid -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-  
20 Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L- $\beta$ -  
cyclohexylalanine)-(D-Glu)-OH (P551);  
-4-tert-butylbenzenesulfonyl-Arg-(D-pipecolic  
acid)-(12-aminododecanoic acid) -4-aminobutyric acid)-  
Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L- $\beta$ -  
25 cyclohexylalanine)-(D-Glu)-OH (P553);  
 $\alpha$ -naphthyl sulfonyl-arginyl D-pipecolic acid -  
(12-aminododecanoic acid) -4-aminobutyric acid)-Asp-  
Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala-(L- $\beta$ -  
cyclohexylalanine)-(D-Glu)-OH (P581);  
30 tert-butylbenzenesulfonyl-Arg (D-Pipecolic acid)-  
(12-aminododecanoic acid)-4-aminobutyric acid)- Asp-  
Phe-Glu-Pro-Ile-Pro-Tyr-OH (BCH-2443);  
tert-butylbenzenesulfonyl-Arg (D-Pipecolic acid)-  
(12-aminododecanoic acid) -4-aminobutyric acid)- Asp-  
35 Phe-Glu-Pro-Ile-Pro-Tyr -OH (BCH-2736);  
tert-butylbenzenesulfonyl-Arg (D-Pipecolic acid)-  
(12-aminododecanoic acid) -4-aminobutyric acid)- Asp-

- Phe-Glu-Pro-Ile-Pro-Tyr -OH (BCH-2741);  
4-bromobenzenesulfonyl-Arg (D-Pipecolic acid)-  
(12-aminododecanoic acid) -4-aminobutyric acid)- Asp-  
Phe-Glu-Pro-Ile-Pro-Tyr -OH (BCH-2733); and  
5 2,4,6 triisopropylbenzensulfonyl-Arg (D-Pipecolic  
acid)- (12-aminododecanoic acid) -4-aminobutyric acid)-  
Asp-Phe-Glu-Pro-Ile-Pro-Tyr -OH (BCH-2444).
19. A compound according to claim 17 wherein said  
10 compound is selected from the group consisting of  
(P448); (P471); (P531); (P532); (P552); (P556); (P540);  
(P534); (P528); (P527); (P500); (P501); (P498); (P513);  
(P535); (P551); (P581); (P553); and (BCH-2733).
- 15 20. A compound according to claim 17 wherein said  
compound is selected from the group consisting of  
(P448); (P531); (P532); (P540); (P552); (P527); (P500);  
(P501); (P513); (P535); (P551); (P553); and (P581).
- 20 21. The use of a compound as defined in anyone of claims  
1, 2, 3, 4, 5, 12, 17, 18, 19, and 20 in the  
manufacture of a medicament for the treatment of  
vascular diseases in a mammal, including human.
- 25 22. A pharmaceutical composition comprising at least one  
compound as defined in anyone of claims 1, 2, 3, 4, 5,  
12, 17, 18, 19, and 20 in an amount effective for  
treating or preventing vascular disease and, a  
pharmaceutically acceptable carrier.
- 30 23. A pharmaceutically acceptable combination for  
treating or preventing vascular disease in a mammal,  
including human, comprising at least one compound as  
defined in anyone of claims 1, 2, 3, 4, 5, 12, 17, 18,  
35 19, and 20; a thrombolytic agent; and a  
pharmaceutically acceptable carrier.


24. The combination according to claim 23 wherein said thrombolytic agent is tissue plasminogen activator.
- 5 25. A method for the treatment or prevention of vascular diseases of a mammal, including human, comprising the administration of an effective amount of a composition according to claim 23.
- 10 26. A method for the treatment or prevention of vascular diseases of a mammal, including human, comprising the administration of an effective amount of a combination according to claim 23.
- 15 27. A method for the treatment or prevention of vascular diseases of a mammal, including human, comprising the administration of an effective amount of a combination according to claim 23.

Figure 1a



SUBSTITUTE SHEET


Figure 1b



SUBSTITUTE SHEET




Figure 2a




SUBSTITUTE SHEET

Figure 2b



SUBSTITUTE SHEET

Figure 2c



**SUBSTITUTE SHEET**

## INTERNATIONAL SEARCH REPORT

Inter:   nal Application No

PCT/CA 94/00585

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 C07K14/815 A61K38/58

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,91 02750 (BIOGEN,INC.) 7 March 1991 cited in the application see the whole document ---	1-18, 21-27
Y	WO,A,91 19734 (NRC) 26 December 1991 cited in the application see the whole document ---	1-18, 21-27
Y	BIOCHEMISTRY, vol. 32, no.13, 6 April 1993 pages 3396-3404, Z.SZEWCZUK ET AL 'Design of a linker for trivalent thrombin inhibitors' see the whole document --- -/--	1-18, 21-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

16 March 1995

Date of mailing of the international search report

27 -03- 1995

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+ 31-70) 340-3016

Authorized officer

Groenendijk, M

# INTERNATIONAL SEARCH REPORT

Inter nal Application No  
PCT/CA 94/00585

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J.MOL.BIOL., vol. 226, 1992 pages 1085-1099, H.BRANDSTETTER ET AL 'Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the menamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA' see the whole document ---	1-18, 21-27
Y	TRENDS IN CARDIOVASC.MED., vol. 1, no.6, September 1991 pages 261-276, L.BADIMON ET AL 'hirudin and other thrombin inhibitors' see the whole document ---	1-18, 21-27
Y	US,A,4 173 630 (S.OKAMOTO ET AL) 6 November 1979 see the whole document ---	1-18, 21-27
P,X	WO,A,93 22344 (CIBA-GEIGI AG) 11 November 1993 see the whole document -----	1-27

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA94/00585

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark : Although claims 25-27 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Application No

PCT/CA 94/00585

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9102750	07-03-91	US-A- 5196404	23-03-93
		AU-B- 652125	18-08-94
		AU-A- 6284190	03-04-91
		CA-A- 2065150	19-02-91
		EP-A- 0489070	10-06-92
		JP-T- 4507253	17-12-92
		US-A- 5240913	31-08-93
WO-A-9119734	26-12-91	AU-B- 654820	24-11-94
		AU-A- 8085591	07-01-92
		EP-A- 0536177	14-04-93
		JP-T- 6500073	06-01-94
US-A-4173630	06-11-79	JP-C- 1167853	08-09-83
		JP-A- 51105046	17-09-76
		JP-B- 57047990	13-10-82
		JP-C- 1165631	26-08-83
		JP-A- 51105047	17-09-76
		JP-B- 57047991	13-10-82
		JP-C- 1294270	16-12-85
		JP-A- 54003037	11-01-79
		JP-B- 60010028	14-03-85
		JP-C- 1264290	16-05-85
		JP-A- 52019653	15-02-77
		JP-B- 59041991	11-10-84
		JP-C- 1240709	26-11-84
		JP-A- 52031061	09-03-77
		JP-B- 59013500	30-03-84
		JP-C- 1240711	26-11-84
		JP-A- 52033662	14-03-77
		JP-B- 59013501	30-03-84
		JP-C- 1240714	26-11-84
		JP-A- 52042863	04-04-77
		JP-B- 59013503	30-03-84
		JP-C- 1189055	13-02-84
		JP-A- 52046059	12-04-77
		JP-B- 58022030	06-05-83
		JP-C- 1052091	30-06-81
		JP-A- 51125052	01-11-76
		JP-B- 55042981	04-11-80